Clinical Research
corporate_fare

Altheia Science S.r.l.

Address
Via Conservatorio 30

Sponsor Overview

assignment
1
sponsored trial
science
1
molecule
location_city
1
research centre
public
1
country
person_search
1
investigator

Specializations

Type 1 diabetes

Altheia Science S.r.l. is engaged in clinical research focused on type 1 diabetes, with interest in early disease management and immune-related metabolic intervention.

  • Autoimmune diabetes
  • Early type 1 diabetes
  • Glycemic regulation

The sponsor’s research activity in this area reflects attention to therapeutic strategies aimed at preserving pancreatic function and addressing the underlying disease process in diabetes mellitus.

Gene therapy

The sponsor’s clinical research includes gene therapy approaches for metabolic disease, with a particular focus on interventions designed to modify disease biology in type 1 diabetes.

  • Genetic medicine
  • Targeted molecular therapy
  • Cell-based gene intervention

Its therapeutic interests extend to treatment concepts that use genetic modification to support disease-specific biological correction.

Stem cell therapy

Altheia Science S.r.l. is also involved in research using patient-derived stem cells, linking regenerative medicine with endocrine and metabolic applications.

  • Autologous stem cells
  • Regenerative medicine
  • Cellular therapy

This area of interest centers on cellular approaches intended to support tissue repair and functional restoration in pancreatic disorders.

Safety evaluation

The sponsor’s active trial portfolio places emphasis on treatment safety in a first-in-human setting, with attention to tolerability in a novel therapeutic context.

  • Clinical safety
  • Therapeutic tolerability
  • Human translational research

Its research activity is concentrated in Milan, Italy, within a single ongoing study in Europe.

Sponsored Trials

Trial Name Country Status
A single-arm, open-label, phase I/II clinical trial of autologous hematopoietic stem and progenitor cells (HSPCs) genetically modified with a lentiviral vector (LVV) encoding for the human programmed death-ligand 1 (hPD-L1) complementary deoxyribonucleic acid (cDNA) for the treatment of patients with type 1 diabetes (T1D) at recent onset and with residual β-cell function (Immunostem)Italy ItalyRecruiting

Data & Insights

science
Molecule Portfolio
Compounds under investigation
1
Exclusive Molecules
out of 1 total (100% not shared with other sponsors)

This sponsor works with 1 molecule, of which 1 is not being studied by other sponsors.

hub
Site Partnerships
Collaboration with research centres
0%
Return partnership rate
0 of 1 sites collaborated multiple times

This sponsor has worked with 1 site across their trial portfolio.

Therapeutic Focus

  • 1.
    Nutritional and Metabolic Diseases1 trial
    211 other sponsors

Partnered Research Centres

1 centre
location_city
assignment392
Azienda Ospedaliera di Padova
Address
Via Nicolo' Giustiniani 2, 35128 Padua
Learn morearrow_forward

Want to get in touch with this sponsor?

Send a question and we'll pass it on to Altheia Science S.r.l..

Need a custom report on this sponsor?

Competitive positioning, market entry, partnership opportunities — tell us the question.

Is something out of date?

Tell us what needs correcting and we'll update this profile.